# 1 Association between COVID-19 mortality and population level health and socioeconomic indicators

- 2 Sasikiran Kandula\*, Jeffrey Shaman
- 3 Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY.
- 6 \*Correspondence:

- 7 sk3542@cumc.columbia.edu
- 8 722 West 168th Street, 1104A
- 9 New York, NY. 10032.

# **Abstract**

With the availability of multiple COVID-19 vaccines and the predicted shortages in supply for the near future, it is necessary to allocate vaccines in a manner that minimizes severe outcomes. To date, vaccination strategies in the US have focused on individual characteristics such as age and occupation. In this study, we assess the utility of population-level health and socioeconomic indicators as additional criteria for geographical allocation of vaccines. Using spatial autoregressive models, we demonstrate that 43% of the variability in COVID-19 mortality in US counties can be explained by health/socioeconomic factors, adjusting for case rates. Of the indicators considered, prevalence of chronic kidney disease and proportion of population living in nursing homes were found to have the strongest association. In the context of vaccine rollout globally, our findings indicate that national and subnational estimates of burden of disease could be useful for minimizing COVID-19 mortality.

Introduction

58 59

22 By the end of 2020, the COVID-19 pandemic has resulted in 81.5 million documented cases and 1.8 million deaths globally 23 (1). The United States has contributed nearly a quarter of these cases and has lost 1 in every 1000 residents to COVID-19 24 25 (2). The outbreak has affected all states in the US but with considerable differences in the trajectory and severity of 26 individual outbreaks. Besides this inter- and intra-state geographical variability, the likelihood of adverse outcomes among 27 those infected is reported to be associated with individual's age, gender, race/ethnicity and underlying health conditions (3-6). An estimated 22% of the global population and 28% of the US have one or more of the underlying conditions that 28 29 pose increased risk of sever outcomes from COVID-19(7). Early studies on clinical characteristics of severe outcomes from COVID-19 were reported from China(5, 8), after the first 30 large outbreak in Wuhan, and concurring estimates were subsequently published from UK, France, US and elsewhere (3, 4, 31 32 9-12). Guan et al (8) reported that among 1100 of the earliest laboratory confirmed cases of COVID-19 in China, the 33 presence of co-morbidities such as diabetes, hypertension and chronic obstructive pulmonary disease were more prevalent in those with severe outcomes (admission to ICU, requiring mechanical ventilation or death), along with a slightly elevated 34 35 risk among men and by now well-established risk with increasing age. Using a larger data sample of 45 thousand cases, Deng et al(5) reported that mortality was associated (relative risk (RR) or hazard ratio (HR)) with cardiovascular disease 36 37 (RR = 6.75, 95%CI = 5.40 - 8.43), hypertension (HR = 4.48, 95%CI = 3.69 - 5.45), diabetes (RR = 4.43, 95%CI = 3.49 - 5.61) and 38 respiratory disease (RR = 3.43, 95%CI = 2.42-4.87, p < 0.001). A later, more extensive study (9) from the UK linking 17 million cases to 11 thousand deaths also found association between 39 40 COVID-19 deaths and kidney disease (HR=2.5, 95%CI = 2.3-2.7), diabetes(HR = 1.95, 95%CI = 1.8-2.1), extreme obesity (HR = 1.9, 95%CI = 1.7-2.1) and several other co-morbidities. From a pooled analysis of 75 studies from multiple countries, 41 Popkin et al(12) summarized that individuals with obesity are at increased risk of death (OR = 1.48; 95% CI, 1.22-1.80) 42 hospitalization (OR = 2.13; 95% CI, 1.74-2.60) and ICU admission (OR = 1.74; 95% CI, 1.46-2.08). Based on these findings 43 and the known prevalence of co-morbidities that existed in the population before the emergence of the pandemic, the 44 populations at risk of severe COVID-19 outcomes at county-level in the US(13) and in several countries have been 45 46 estimated (7). Other studies have examined the associations of socioeconomic characteristics including poverty, income and race/ethnicity (14-16). 47 Over the past year, public health attempts to reduce transmission largely centered on non-pharmaceutical interventions 48 such as social distancing, face coverings and hand hygiene. In the US, these interventions have had limited success and part 49 of this failure stems from their dependence on collective compliance. The recent availability of high efficacy vaccines gives 50 individuals an additional tool to protect themselves (vaccine supply permitting), and importantly, does not require 51 52 cooperation from collective public. The availability of vaccines also implies an opportunity to refocus our efforts at reducing infections from efforts at reducing 53 54 severe outcomes by prioritizing vaccination for those at a higher risk of severe outcomes. To date such strategies have been largely guided by individual characteristics such as age and occupation. We hypothesize that population level 55 characteristics can also guide the optimal allocation and distribution of vaccines geographically. This points to a potential 56 57 two-layered approach of first identifying high-risk communities within which high-risk individuals can be prioritized.

Here, we assess the feasibility of the first part of such an approach and evaluate the extent to which the geographical variability of mortality in US can be explained by population characteristics that predate the epidemic. Our outcome of 60 interest is COVID-19 associated mortality rates at county resolutions, which we attempt to model as a function of population

health and socioeconomic indicators. An initial set of indicators associated with COVID-19 mortality as reported in peer-

reviewed studies, and data sources for estimates of these indicators were identified. A smaller subset of the variables were

selected based on the correlation between the variables and their independent effects on the response.

Conventional regression models assume that observations are independent of one another, which in the case of spatial data

translates to assuming observations in nearby locations are no more closely related than those farther away. Given the

transmission dynamics of COVID-19, counties nearby are likely to be have similar case and death rates and spatial

dependence rather than spatial independence is a more appropriate assumption. This spatial dependence also extends to

health and socioeconomic indicators and potentially latent and unobservable characteristics that effect mortality.

69 Spatial autoregressive (SAR) models offer a parsimonious way to augment basic regression models with spatial dependence

between locations (17), and are an extensively studied family of analytical approaches with applications ranging from

econometrics, environmental studies and health sciences (18-20). In the current study, we first establish the presence of

spatial autocorrelation in the response and explanatory variables, thus motivating the need for spatial models. We apply

three forms of SAR models, show that they explain a greater proportion of the variability in mortality than linear models

74 and report effect estimates from each.

## **Data and Methods**

- 76 County level indicators of population's health and social status were retrieved from public sources including the US census
- 77 and large population surveys. In cases where the survey data are not available at county resolutions, data from prior studies
- on small-area estimates were used. We tried to limit the number of source dependencies and when alternative estimates
- 79 were available from multiple sources, we preferred estimates from the US Centers for Disease Control and Prevention
- 80 (CDC). See Table 1 for a list of sources and descriptions for each variable; Figure 1 presents summary statistics.
- 81 New York Times

61

62 63

64

65

66

67

68

71 72

73

- 82 Counts for cumulative cases and deaths through December 31, 2020 were retrieved from New York Times public repository
- 83 (21). These data included both confirmed and probable cases and deaths at the US county-level and is based on Times'
- monitoring and analyses of news conferences, data releases and communications with public officials. The determination
- 85 of cases and deaths as either confirmed or probable is made per definitions laid out in the position statement of the Council
- of State and Territorial Epidemiologists (22). But as the application can vary across local agencies, here we treat both
- 87 confirmed and probably categories identically and use total cases and deaths. Case and death rates as a proportion of
- residents are based on county population estimates from the American Community Survey (ACS) 2014-2018(23).
- 89 County-specific data for the 5 counties in New York City were retrieved from USAFACTS (24) as the Times' data source was
- 90 found to combine counts for these five counties into a single entity. Figure 2 shows maps of reported county case and death
- 91 rates.
- 92 Population Level Analysis and Community Estimates (PLACES)
- 93 From the PLACES study(25), a collaboration between the CDC and Robert Wood Johnson Foundation, estimates for
- 94 population-level health and behavioral indicators were retrieved. These small-area estimates of population health
- 95 outcomes across the US at county resolutions were generated using data collected through the Behavioral Risk Factor

96 Surveillance System (BRFSS)(26), the US decennial 2010 census and the ACS, following a multi-level regression and post-

97 stratification approach (27, 28).

98

99

100101

102

103104

105

106107

108

112

113

114115

116

119

120

121

122

123124

125

127

128

129

130

131

Of the 27 indicators available in PLACES, we extracted 5 measures of population level prevalence of health conditions that

are reported to have individual level associations with COVID-19 outcomes, namely obesity, diabetes, chronic obstructive

pulmonary diseases and chronic heart and kidney diseases. In addition, three related health indicators, the prevalence of

high blood pressure and high cholesterol and proportion of residents uninsured were also included.

Social Vulnerability Index

CDC's Social Vulnerability Index (SVI) is a measure of a county's relative vulnerability to hazardous events (29, 30) and is

intended to help public officials and planners better prepare for such events. Overall, county ranks are based on fifteen

socioeconomic indicators collected in the ACS. Three of the factors in the SVI, namely county population density, median

per capita income and proportion of the population that is older than 65 years of age, are hypothesized to be associated

with COVID-19 mortality (14, 15, 31, 32). As association between the other variables in SVI and COVID-19 is uncertain, we

limited inclusion to the raw estimates of these 3 variables and ignore the other variables in SVI and the overall index.

109 County Health Rankings

Two additional variables derived from the ACS 2014-18 and available through the County Health Rankings (CHR)(33), are

hypothesized to be measures of socioeconomic disparities in a county and included in this study: ratio of the 80th percentile

income to 20th percentile as a measure of income inequality, and the proportion of non-White to White residents as a

measure of racial diversity. We observed that estimates for these variables in a small percentage ( $\sim 1.5\%$ ) of counties were

missing and used the following three-step process to impute missing values: a) the mean of neighboring (defined in later

sections) counties that have estimates; b) if there are no neighbors with estimates, the median of all counties in the state

for which estimates are available; c) if estimates are missing for all counties in a state, the median across all counties in the

117 US for which estimates are available.

118 US 2010 Census

It has also been reported that COVID-19 clusters occur in facilities in which people live in group quarters, where the

increased vulnerability can result from either the living conditions in such facilities (difficulty to social distance in

correctional facilities or on college campuses, for example) or the characteristics of the residents (elderly in nursing homes

with underlying health conditions) (34, 35). As mortality from COVID-19 is known to be less likely in younger populations,

we focused instead on elderly living in group quarters. An estimate of proportion of the population living in nursing homes

or facilities with skilled-nursing in each county was included in this analysis (Table 1).

### Methods overview

We first built linear univariate models for each predictor with county-level COVID-19 mortality as outcome, adjusting for

county case rates. These models inform both the individual effects and the proportion of variance in mortality explained by

each of these predictors. We followed this with a linear multivariate model, again adjusting for case rates. In both univariate

and multivariate models, observational independence is inappropriate because of spatial autocorrelation in both the

response and predictors. We verify this by standard tests on the residual of the multivariate model. We finally build spatial

simultaneous autoregressive models and report effect estimates.

Spatial weight matrix and spatial autocorrelation

As introduced in an earlier section, a key assumption in standard ordinary least square regression (OLS) models is the independence of observations that does not hold because COVID-19 cases and deaths in a county are related to cases and deaths in other counties (spatial dependence) and often counties adjacent to it (spatial autocorrelation). Models that do not account for spatial dependence and autocorrelation are shown to have inflated type I errors (20, 36).

To establish adjacency of counties in the US, we define a simple spatial  $n \times n$  matrix, **W**, using shape files that list county boundaries as an ordered set of geocoded reference points (37). County adjacency is defined by queen congruity (at least one shared boundary point) and the spatial weight matrix is row standardized i.e. for each county i, the weight of link to county j,  $w_{ij}$ , is the inverse of the number of neighbors of i, if j is adjacent to i, and 0 otherwise;  $\sum_j w_{ij} = 1$ . A county is assumed to not be a neighbor of itself i.e.  $w_{ij} = 0$  when i = j.

Moran's I(38, 39), a commonly used measure of global spatial autocorrelation, is calculated as:

$$I = \frac{n * \sum_{i=1}^{n} \sum_{j=1}^{n} w_{ij} (x_i - \bar{x}) (x_j - \bar{x})}{(\sum_{i} \sum_{j} w_{ij}) (\sum_{i=1}^{n} (x_i - \bar{x})^2)}$$

where n is the number of counties,  $x_i$  is the variable of interest for county i,  $\bar{x}$  is the mean across all counties and  $w_{ij}$  is as defined by the spatial weight matrix,  $\mathbf{W}$ . Here, as  $\mathbf{W}$  is row standardized  $\sum_i \sum_j w_{ij} = n$  and the above equation can be simplified. The significance of the statistic was tested under the randomization assumption i.e.  $x_i$  are draws from a random distribution and there is no spatial association. A related measure to identify specific regions within the study region that exhibit spatial autocorrelation, the Local Moran's I, was also estimated. Figure 3 shows Moran's I and counties with significant(40) Local Moran's I and for each predictor and outcome.

We were also interested in determining whether spatial autocorrelation, if present, resided in the response or in the residual, as this also informs the choice of the spatial model. To identify this we used robust Lagrange Multiplier tests that can detect possible autocorrelated residuals in the presence of an omitted lagged response and vice versa (41, 42). The statistics reported here are from implementations of these tests in the *spdep* (39, 43) R(44) library.

Variable pruning

As the variables selected for inclusion are related, we calculated Spearman's correlation between pairs of variables (Figure 4) and found some of the variables to be very highly correlated. Hence, it would not be appropriate to include these pairs together in models. We used the results of the univariate analysis, to aid variable selection by only retaining those variables that have a correlation of less than .75 with variables of a higher  $R^2$ . This led to the elimination of five variables – prevalence indicators for diabetes, heart disease, high blood pressure (all highly collinear with kidney disease), high cholesterol (collinear with COPD) and median per capita income. The linear multivariate model and the spatial models were built using this smaller set of predictors (n = 9).

Spatial simultaneous autoregressive models (SAR)

The general form of an autoregressive model in spatial statistics is given by (17, 20, 45):

$$164 y = X\beta + \rho Wy + \lambda Wu + \varepsilon$$

167168

169170

171

172173

174175

176177

178

179

180

181

182

183

184

185 186

187

188

189 190

191

192 193

194

195

196

197

198

199200

where y is a  $n \times 1$  vector of the response variable,  $\mathbf{X}$  is a  $n \times k$  matrix of k predictors for n counties,  $\mathbf{W}$  is the  $n \times n$  spatial weight matrix,  $\rho$  is the spatial autoregressive *lag* coefficient and  $\lambda$  the spatial *error* coefficient and  $\beta$ , u the coefficient and error vectors respectively. When  $\lambda = 0$ , the autoregressive process is assumed to occur in the response only (captured by  $\rho$ **W**) and the model is referred to as a spatial lag model. When  $\rho = 0$ , the autoregressive process is assumed to occur only in the errors (captured by  $\lambda W$ ), and the model referred to as spatial error model. Model implementations are per spatialreg (43, 45, 46) library in R. Results Results from the univariate analysis indicate that the selected variables individually explain 24-29% of the variability in mortality, adjusting for case rates. Mortality is estimated to increase by 43 per thousand residents (95% CI: 37-49) for every 1% increase in prevalence of chronic kidney disease, and by 10.4 (95% CI: 8-13) for chronic heart disease, 7.4 (95% CI: 6-8) for diabetes, 4.4 (95% CI: 3-5.8) for COPD, 3.7 (95% CI: 2.6-5.8) for high cholesterol, 2.8 (95% CI: 2.2-3.3) for high blood pressure and 2.6 (95% CI: 2-3.2) for obesity prevalence respectively (Figure 5). These health indicators also explain 28%, 25.5%, 27.5%, 24.6%, 24.6%, 25.9% and 25.3% of the variability respectively. Among socioeconomic indicators, the largest association was seen with the nursing home variable (Adjusted R2: 29%) with an estimated increase of 39 deaths per thousand (95% CI: 34-44) for every 1% increase in percent living in nursing homes. Mortality rates are estimated to increase by 2.8 (95%CI: 2.3-3.4) and 2.4 (95% CI: 2-2.9) for each 1% increase in percentage of the population who are elderly (65+ years) and uninsured 18-64 year olds, respectively. In contrast, mortality rate is estimated to decrease by 1.5 (95% CI: 1.05-1.87) for every thousand dollar increase in per capita income. On average, the R<sup>2</sup> estimates for socioeconomic indicators are lower than for health indicators. Following variable pruning to correct for collinearity, the multivariate model explained 38% of the variability in mortality with a few changes in effect estimates. Obesity's association is not statistically significant in the presence of kidney disease and COPD's association is counterintuitively negative (Table 2). Moran's I test for spatial autocorrelation in residuals of the above model was found to be statistically significant (18.4, p < 1E-6). Both robust LM tests were found to be significant indicating possible autocorrelation in both the error (28.7, p < 1E-6) and response (33.5, p < 1E-6). Hence, three model forms, the general SAR model, spatial lag and spatial error models were attempted. The proportion of variability explained by the SAR models is about 14% higher than the linear model (Figure 6). The spatial error model had an Nagelkerke R<sup>2</sup> (47) of 43.5% with an estimated autocorrelation error coefficient (λ) of .418 (95%CI: .37 - .46). The spatial lag model and the general model were observed to have an R<sup>2</sup> nearly identical to that of the error model, The autocorrelation coefficient in response (ρ) was found to be .347 (95%CI: .31-.39) for the spatial model, but when both coefficients were estimated simultaneously in a general model, the lag coefficient was found to be not significant:  $\lambda = .336$ (95%CI: .244-.429);  $\rho = .083 (95\%CI: .007 - .174$ ; p=.07). Figure 7 shows the spatial lag model's estimates and residuals. The Global Moran's test on the residuals of all three models found no significant spatial autocorrelation (p > .05). Effect

estimates for inequality variable were found to be not significant (p > .05) in any of the spatial models (Figure 6). The

negative association of COPD seen in the linear model is also observed with the spatial models. Obesity, as in the linear

model, was found to be not statistically significant in two of the spatial models.

203

204

205

206

207

208209

210

211212

213

214

215

216

217

218

219

220

221222

223

224

225

226

227

228229

230231

232233

234

235

236

237

To test for sensitivity of models' R2 to the variable pruning method, we additionally subset variables using alternative spearman correlation thresholds of .5, .65 and .85 and built linear and spatial models with each. Figure 8 shows that R2 was not sensitive to the value of threshold and the spatial models have a consistently higher R2 than the linear model. Discussion We have built models to estimate COVID-19 mortality rates for given case rates and population health and socioeconomic characteristics. Our results indicate that together these indicators can explain 43% of the variability in US county mortality rates, when spatial autocorrelation is accounted for. We found that among health indicators considered the prevalence of chronic kidney disease and among socioeconomic indicators the proportion living in nursing homes, have the largest associations with mortality. The choice and timeliness of control strategies in response to an outbreak do affect its progress and caseload. Our findings here show that differential risks of severe outcomes from COVID-19 across populations can be in part estimated from the structures and contexts in which the outbreak occurs, for example, a population's quality of health, its access to healthcare and the disparities therein. With the availability of vaccines, these population level indicators can serve as criteria for prioritizing geographical allocation of vaccines. These findings may also be relevant to low- and middle-income countries (LMIC). It has been reported that almost all of the Pfizer-BioNTech and Moderna vaccine doses to be manufactured through the end of 2021 have been purchased and are reserved for distribution in the US, Canada, UK and the EU (48, 49). Of the 42 countries that have rolled out vaccines by early January 2021, only 6 are middle-income countries and none are low-income countries (50). The COVAX initiative with participation from governments of several LMIC countries, the WHO and partner non-governmental organizations, aims to achieve equitable and affordable access to vaccines globally through a common vaccine purchase and allocation framework (51). When allocation decisions need to span multiple countries, national and subnational socioeconomic indicators and burden of disease estimates can potentially be leveraged to reduce overall risk of severe outcomes from COVID-19 as our findings demonstrate. This study has a few limitations. Case and death counts were retrieved a week after the end of the study period. Given the lags in data reporting, particularly with deaths, events occurring at the end of the study period may not have been recorded and the rates used are underestimates. Similarly, the outcomes may not yet be known for cases recorded near the end of the study period. The adjacency based spatial weight matrix that was used in this study does not sufficiently capture the spread of COVID-19. Cases that occur in a county are not only correlated with those in counties geographically adjacent to it but also with counties with which it has strong population mixing; for example, counties with metropolitan centers into which commuters travel from the suburbs, or counties with major airports. Spatial weight matrices that capture mobility patterns may be more appropriate and lead to better spatial models. Similarly, methods that can explicitly account for spatial autocorrelation in predictors remain to be explored. Finally, the model structure presented may not be parsimonious in the number of predictors. Although we dropped a third of the predictors initially considered (to correct observed collinearity), model forms with a smaller subset of independent variables may yield near identical R<sup>2</sup> and need to be explored. This is also belied by the lack of significance of some of the predictors included in the spatial models. One approach could start with a minimal set of predictors, incrementally add

- 238 predictors while evaluating goodness of the resulting model in each iteration and terminating when the improvement is
- below a threshold. Similarly, the variable pruning discussed above is ad hoc; the variables included in the model may be
- interchangeable with those discarded with only marginal change in model performance.

## References

- 242 1. WHO Coronavirus Disease (COVID-19) Dashboard 2020 [Available from: https://covid19.who.int/.
- 243 2. CDC Case Task Force. United States COVID-19 Cases and Deaths by State over Time 2021 [Available from: https://data.cdc.gov/Case-Surveillance/United-States-COVID-19-Cases-and-Deaths-by-State-o/9mfg-cb36.
- 3. Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–
- 247 March 28, 2020. 2020.
- 4. CDC. Coronavirus disease 2019 (COVID-19). Evidence used to update the list of underlying medical conditions that increase a person's risk of severe illness from COVID-19. 2020.
- 5. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. Critical Care. 2020;24(1):1-3.
- 6. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, Felix SEB, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. Morbidity and Mortality Weekly Report. 2020;69(24):759.
- 7. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HH, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health. 2020;8(8):e1003-e17.
- 8. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China.
  New England journal of medicine. 2020;382(18):1708-20.
- 9. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.
- Docherty AB, Harrison EM, Green CA, Hardwick H, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients
   with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medrxiv. 2020.
- 11. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020.
- 12. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obesity Reviews. 2020;21(11):e13128.
- 13. Razzaghi H, Wang Y, Lu H, Marshall KE, Dowling NF, Paz-Bailey G, et al. Estimated county-level prevalence of selected
   underlying medical conditions associated with increased risk for severe COVID-19 illness—United States, 2018.
   Morbidity and Mortality Weekly Report. 2020;69(29):945.
- 270 14. Adhikari S, Pantaleo NP, Feldman JM, Ogedegbe O, Thorpe L, Troxel AB. Assessment of community-level disparities in 271 coronavirus disease 2019 (COVID-19) infections and deaths in large US metropolitan areas. JAMA network open. 272 2020;3(7):e2016938-e.
- 15. Baena-Díez JM, Barroso M, Cordeiro-Coelho SI, Díaz JL, Grau M. Impact of COVID-19 outbreak by income: hitting hardest the most deprived. Journal of Public Health. 2020;42(4):698-703.
- 16. Townsend MJ, Kyle TK, Stanford FC. Outcomes of COVID-19: disparities in obesity and by ethnicity/race. Nature Publishing Group; 2020.
- 17. LeSage JP. An introduction to spatial econometrics. 2008(123):19-44.

- 18. Fischer MM, Getis A. Handbook of applied spatial analysis: software tools, methods and applications: Springer Science & Business Media; 2009.
- 19. LeSage JP, Pace RK. Spatial econometric models. Handbook of applied spatial analysis: Springer; 2010. p. 355-76.
- 20. F. Dormann C, M. McPherson J, B. Araújo M, Bivand R, Bolliger J, Carl G, et al. Methods to account for spatial autocorrelation in the analysis of species distributional data: a review. Ecography. 2007;30(5):609-28.
- 21. Coronavirus (Covid-19) Data in the United States [Internet]. 2020 [cited 1/11/2021]. Available from: https://github.com/nytimes/covid-19-data.
- 22. Council of State and Territorial Epidemiologists. Coronavirus Disease 2019 (COVID-19) 2020 Interim Case Definition

  [Available from: <a href="https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/">https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/08/05/</a>.
- 23. U.S. Census Bureau. 2014-2018 American Community Survey 5-year Public Use Microdata Samples 2019
- 24. USAFACTS. Coronavirus data resource [Available from: <a href="https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/">https://usafacts.org/visualizations/coronavirus-covid-19-spread-map/</a>.
- 25. Centers for Disease Control and Prevention. PLACES Project [Available from: <a href="https://www.cdc.gov/places">https://www.cdc.gov/places</a>.
- 26. Remington PL, Smith MY, Williamson DF, Anda RF, Gentry EM, Hogelin GC. Design, characteristics, and usefulness of state-based behavioral risk factor surveillance: 1981-87. Public health reports. 1988;103(4):366.
- 27. Zhang X, Holt JB, Lu H, Wheaton AG, Ford ES, Greenlund KJ, et al. Multilevel regression and poststratification for smallarea estimation of population health outcomes: a case study of chronic obstructive pulmonary disease prevalence using the behavioral risk factor surveillance system. American journal of epidemiology. 2014;179(8):1025-33.
- 28. Zhang X, Holt JB, Yun S, Lu H, Greenlund KJ, Croft JB. Validation of multilevel regression and poststratification methodology for small area estimation of health indicators from the behavioral risk factor surveillance system.
- 299 American journal of epidemiology. 2015;182(2):127-37.
- 29. Flanagan BE, Gregory EW, Hallisey EJ, Heitgerd JL, Lewis B. A social vulnerability index for disaster management.

  Journal of homeland security emergency management. 2011;8(1).
- 30. Centers for Disease Control and Prevention. Social Vulnerability Index [Available from: <a href="https://www.atsdr.cdc.gov/placeandhealth/svi/index.html">https://www.atsdr.cdc.gov/placeandhealth/svi/index.html</a>.
- 31. Lamb MR, Kandula S, Shaman J. Differential COVID-19 case positivity in New York City neighborhoods: Socioeconomic
   factors and mobility. Influenza & Other Respiratory Viruses. 2020.
- 32. Sannigrahi S, Pilla F, Basu B, Basu AS, Molter A. Examining the association between socio-demographic composition and COVID-19 fatalities in the European region using spatial regression approach. Sustainable cities society. 2020;62:102418.
- 33. Remington PL, Catlin BB, Gennuso KP. The county health rankings: rationale and methods. Population health metrics. 2015;13(1):11.
- 34. Abrams HR, Loomer L, Gandhi A, Grabowski DC. Characteristics of US Nursing Homes with COVID-19 Cases. Journal of the American Geriatrics Society. 2020.
- 35. Barnett ML, Grabowski DC, editors. Nursing homes are ground zero for COVID-19 pandemic. JAMA Health Forum; 2020: American Medical Association.
- 36. Anselin L. Under the hood issues in the specification and interpretation of spatial regression models. Agricultural economics. 2002;27(3):247-67.
- 37. U.S. Census Bureau. Catrographic Boundary Files Shapefile 2018 [Available from: https://www.census.gov/geographies/mapping-files/time-series/geo/carto-boundary-file.html.


- 38. Cliff AD, Ord JK. Spatial processes: models & applications: Taylor & Francis; 1981.
- 39. Bivand RS, Wong DW. Comparing implementations of global and local indicators of spatial association. Test. 2018;27(3):716-48.
- 40. Anselin L. Local indicators of spatial association—LISA. Geographical analysis. 1995;27(2):93-115.
- 323 41. Anselin L. Spatial econometrics: methods and models: Springer Science & Business Media; 2013.
- 42. Anselin L, Bera AK, Florax R, Yoon MJ. Simple diagnostic tests for spatial dependence. Regional science urban economics. 1996;26(1):77-104.
- 43. Bivand RS, Pebesma EJ, Gómez-Rubio V, Pebesma EJ. Applied spatial data analysis with R: Springer; 2008.
- 44. Team RC. R: A language environment for statistical computing. R Foundation for Statistical Computing: version 3.5. 0. 2018.
- 45. Bivand R, Piras G, editors. Comparing implementations of estimation methods for spatial econometrics 2015: American Statistical Association.
- 46. Bivand R, Hauke J, Kossowski T. Computing the J acobian in G aussian Spatial Autoregressive Models: An Illustrated Comparison of Available Methods. Geographical Analysis. 2013;45(2):150-79.
- 47. Nagelkerke NJ. A note on a general definition of the coefficient of determination. Biometrika. 1991;78(3):691-2.
- 48. LaFraniere S, Thomas K, Weiland N. Trump administration officials passed when Pfizer offered months ago to sell the U.S. more vaccine doses. The New York Times. 2020. 12/07/2020.
- 49. Mullard A. How COVID vaccines are being divvied up around the world. 2020 11/30/2020.
- 50. Director-General's opening remarks at the media briefing on COVID-19 8 January 2021 [press release]. 1/8/2021.
- 338 51. COVAX. GAVI Alliance [Available from: <a href="https://www.gavi.org/covax-facility">https://www.gavi.org/covax-facility</a>.

Variable	Source	Description; primary source	
Deaths	New York Times(21),	Cumulative COVID-19 confirmed and probable deaths through	
	USAFACTS(24)	December 31 2020; per thousand residents	
Cases	New York Times,	Cumulative COVID-19 confirmed and probable cases through	
	USAFACTS	December 31 2020; per 100000 residents	
Obesity	PLACES(25)	Proportion of residents 18+ years of age with calculated BMI ≥	
		30 kg/m <sup>2</sup> , based on self-reported weight and height; BRFSS(26)	
Diabetes	PLACES	Proportion of residents 18+ years of age who report being told	
		by a doctor/nurse/other health professional that they have type	
		1 or type 2 diabetes; BRFSS	
Chronic kidney disease	PLACES	Proportion of residents 18+ years of age who report being told	
(CKD)		by a doctor/nurse/other health professional that they have	
		kidney disease; BRFSS	
Chronic heart disease	PLACES	Proportion of residents 18+ years of age who report being told	
(CHD)		by a doctor/nurse/other health professional that they have	
		angina or coronary heart disease; BRFSS	
Chronic obstructive	PLACES	Proportion of residents 18+ years of age who report being told	
pulmonary disease (COPD)		by a doctor/nurse/other health professional that they have	
		COPD, emphysema, or chronic bronchitis; BRFSS	
High cholesterol	PLACES	Proportion of residents 18+ years of age who report being told	
		by a doctor/nurse/other health professional that they have high	
		cholesterol; BRFSS	
High blood pressure	PLACES	Proportion of residents 18+ years of age who report being told	
		by a doctor/nurse/other health professional that they have high	
*** 1	DI ACEC	blood pressure; BRFSS	
Uninsured	PLACES	Proportion of residents 18-64 years of age who report having no	
D 1 1	0.11(30)	health insurance coverage	
Population density	SVI(30)	Number of residents per square mile; Census Cartographic	
•	OT II	Boundary File - U.S. Tracts 2018(37)	
Income	SVI	Median per capita income (in 100 thousand US\$); American	
P11 1	OT II	Community Survey, 2014-2018 (5-year)(23)	
Elderly	SVI	Proportion of residents 65+ years of age; American Community	
	***************************************	Survey, 2014-2018 (5-year)	
Group quarters - nursing	US 2010 Census	Proportion of residents living in nursing/skilled-nursing	
	CVID (O.O.)	facilities; P042	
Inequality	CHR(33)	Ratio of household income at 80 <sup>th</sup> percentile with income at 20 <sup>th</sup>	
5 11 11	aven.	percentile; American Community Survey, 2014-2018 (5-year)	
Resident diversity	CHR	Proportion of non-White resident to White residents; American	
		Community Survey, 2014-2018 (5-year)	


 Table 1. Descriptions and sources for variables included in the study.

	Estimate	95% CI	p
(Intercept)	-2.007	(-2.27, -1.74)	<0.001
cases	1.26E-4	(1.16E-4, 1.36E-4)	< 0.001
obesity	-0.654	(-1.43, .13)	0.101
copd	-4.681	(-6.64, -2.72)	< 0.001
ckd	53.48	(41.11, 65.84)	< 0.001
groupq.nursing	41.66	(36.27, 47.08)	<0.001
uninsured	1.479	(.92, 2.03)	< 0.001
elderly	2.449	(1.87, 3.03)	< 0.001
inequality	0.046	(0.005, .087)	0.029
pop.density	3.4E-5	(1.9E-5, 4.8E-5)	< 0.001
res.diversity	0.557	(0.36, .75)	<0.001


**Table 2.** Results of multivariate analysis with linear model, adjusting for case rate. Adjusted  $R^2$  = .3812; F-statistic = 194. (p-value: < .001)




**Figure 1**. Violin plots of distribution for each variable among counties in the US, along with median (interquartile range) in blue and mean (standard deviation) in green.




**Figure 2**. COVID-19 cases (per 100000 residents) and deaths (per 1000 residents) in US counties through December 31, 2020.




**Figure 3.** Local Moran's I statistic for spatial autocorrelation for all measures and outcome. Only counties where the statistic is significant (p < .05) are shown. Significance is tested under Pr[I - E(I)/Var(I)] as given by Anselin(40). Global Moran's I statistic is denoted by the label in each subpanel and found to be statistically significant for all variables.




**Figure 4**. Pairwise surface plots (below diagonal), Spearman correlation (above diagonal) and density (diagonal) of outcome and measures used in the study. \* indicates level of statistical significance of the correlation: p < 0.001 (\*\*\*);  $0.001 \le p < 0.01$  (\*\*);  $0.01 \le p < 0.05$  (\*).




**Figure 5.** Estimates (95% CI) of health and socioeconomic indicators in a linear univariate model with death rate as outcome and adjusting for COVID-19 case rates. Labels indicate adjusted R<sup>2</sup>. Inset magnifies select variables of smaller estimates.



**Figure 6.** Variables estimates with linear and three spatial regression models. p-values indicated when p > .05.



**Figure 7**. Observed death rate (as in Figure 2), model fit and residual of the spatial lag model.



**Figure 8**. Sensitivity of Adhusted R<sup>2</sup> to Spearman correlation threshold used in variable pruning.